Blossomhill Therapeutics Inc. has patented new EGFR (HER1; erbB1) mutant inhibitors that are potentially useful for the treatment of cancer.

Therapex Co. Ltd. has identified pyrimidine derivatives acting as EGFR (HER1; erbB1) mutant inhibitors described as potentially useful for the treatment of cancer.

Blueprint Medicines Corp. has disclosed EGFR mutant inhibitors reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).

Researchers from the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and the Shanghai Institute of Organic Chemistry have divulged EGFR (L858R/T790M/C797S triple mutant) and EGFR (del19/T790M/C797S triple mutant) inhibitors reported to be useful for the treatment of cancer.

Abbisko Therapeutics Co. Ltd. has identified EGFR mutant inhibitors reported to be useful for the treatment of cancer.

Allorion Therapeutics Inc. has disclosed EGFR (HER1; erbB1) mutant inhibitors reported to be useful for the treatment of cancer.

Voronoi Inc. has discovered EGFR (Leu858Arg/Thr790Met/Cys797Ser triple mutant) and EGFR (del19/Thr790Met/Cys797Ser triple mutant) inhibitors.

Schrodinger Inc. has synthesized EGFR (HER1; erbB1) (mutant) inhibitors reported to be useful for the treatment of cancer.

Researchers from Janssen Biotech Inc. and Yuhan Corp. have synthesized EGFR (HER1; erbB1) (mutant) inhibitors reported to be useful for the treatment of cancer and immunological disorders.

Betta Pharmaceuticals Co. Ltd. has synthesized EGFR (HER1; erbB1) mutant inhibitors reported to be useful for the treatment of cancer.